Nucleic Acid Delivery for Endothelial Dysfunction in Cardiovascular Diseases
References
- Mozaffarian D , Benjamin EJ , Go AS , Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation. 2016 Jan 26; 133( 4): e38– e360.
- Lam CS Brutsaert DL. Endothelial dysfunction: a pathophysiologic factor in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2012 Oct 30; 60( 18): 1787– 9.
- Sena CM , Pereira AM , Seica R. Endothelial dysfunction - a major mediator of diabetic vascular disease. Biochim Biophys Acta. 2013 Dec; 1832( 12): 2216– 31.
- Su JB. Vascular endothelial dysfunction and pharmacological treatment. World J Cardiol. 2015 Nov 26; 7( 11): 719– 41.
- Zhang Y , Janssens SP , Wingler K , Schmidt HH , Moens AL. Modulating endothelial nitric oxide synthase: a new cardiovascular therapeutic strategy. Am J Physiol Heart Circ Physiol. 2011 Sep; 301( 3): H634– 46.
- Bäck M Hansson GK. Anti-inflammatory therapies for atherosclerosis. Nat Rev Cardiol. 2015 Apr; 12( 4): 199– 211.
- Beckman JA Creager MA. The nonlipid effects of statins on endothelial function. Trends Cardiovasc Med. 2006 Jul; 16( 5): 156– 62.
- Schwartz BG , Jackson G , Stecher VJ , Campoli-Richards DM , Kloner RA. Phosphodiesterase type 5 inhibitors improve endothelial function and may benefit cardiovascular conditions. Am J Med. 2013 Mar; 126( 3): 192– 9.
- Deshpande DD , Janero DR , Amiji MM. Therapeutic strategies for endothelial dysfunction. Expert Opin Biol Ther. 2011 Dec; 11( 12): 1637– 54.
- Cooke JP. Flow, NO, and atherogenesis. Proc Natl Acad Sci U S A. 2003 Feb 4; 100( 3): 768– 70.
- Blanco E , Shen H , Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015 Sep; 33( 9): 941– 51.
- Dobson J. Gene therapy progress and prospects: magnetic nanoparticle-based gene delivery. Gene Ther. 2006 Feb; 13( 4): 283– 7.
- Pack DW , Hoffman AS , Pun S , Stayton PS. Design and development of polymers for gene delivery. Nat Rev Drug Discov. 2005 Jul; 4( 7): 581– 93.
- Pissuwan D , Niidome T , Cortie MB. The forthcoming applications of gold nanoparticles in drug and gene delivery systems. J Control Release. 2011 Jan 5; 149( 1): 65– 71.
- Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005 Feb; 4( 2): 145– 60.
- Aird WC. Endothelial cell heterogeneity. Cold Spring Harb Perspect Med. 2012 Jan; 2( 1): a006429.
- Chiu JJ Chien S. Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives. Physiol Rev. 2011 Jan; 91( 1): 327– 87.
- Higashi Y , Noma K , Yoshizumi M , Kihara Y. Endothelial function and oxidative stress in cardiovascular diseases. Circ J. 2009 Mar; 73( 3): 411– 8.
- Deanfield JE , Halcox JP , Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007 Mar 13; 115( 10): 1285– 95.
- Vita JA. Endothelial function. Circulation. 2011 Dec 20; 124( 25): e906– 12.
- Rajendran P , Rengarajan T , Thangavel J , The vascular endothelium and human diseases. Int J Biol Sci. 2013 Nov 9; 9( 10): 1057– 69.
- Yang XF , Yin Y , Wang H. Vascular inflammation and atherogenesis are activated via receptors for PAMPs and suppressed by regulatory T cells. Drug Discov Today Ther Strateg. 2008; 5( 2): 125– 142.
- Zimmer S , Steinmetz M , Asdonk T , Activation of endothelial toll-like receptor 3 impairs endothelial function. Circ Res. 2011 May 27; 108( 11): 1358– 66.
- Lee J , Sayed N , Hunter A , Activation of innate immunity is required for efficient nuclear reprogramming. Cell. 2012 Oct 26; 151( 3): 547– 58
- Witztum JL Lichtman AH. The influence of innate and adaptive immune responses on atherosclerosis. Annu Rev Pathol. 2014; 9: 73– 102.
- Davignon J Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation. Jun 15 2004; 109( 23 Suppl 1): III27– 32.
- Galán M , Kassan M , Kadowitz PJ , Trebak M , Belmadani S , Matrougui K. Mechanism of endoplasmic reticulum stress-induced vascular endothelial dysfunction. Biochim Biophys Acta. 2014 Jun; 1843( 6): 1063– 75.
- Kluge MA , Fetterman JL , Vita JA. Mitochondria and endothelial function. Circ Res. 2013 Apr 12; 112( 8): 1171– 88.
- Wenceslau CF1 , McCarthy CG , Szasz T , Spitler K , Goulopoulou S , Webb RC ; Working Group on DAMPs in Cardiovascular Disease. Mitochondrial damage-associated molecular patterns and vascular function. Eur Heart J. 2014 May; 35( 18): 1172– 7.
- Shao Y , Cheng Z , Li X , Chernaya V , Wang H , Yang XF. Immuno-suppressive/anti-inflammatory cytokines directly and indirectly inhibit endothelial dysfunction--a novel mechanism for maintaining vascular function. J Hematol Oncol. 2014 Oct 31; 7: 80.
- Mikhed Y , Daiber A , Steven S. Mitochondrial Oxidative Stress, Mitochondrial DNA Damage and Their Role in Age-Related Vascular Dysfunction. Int J Mol Sci. 2015 Jul 13; 16( 7): 15918– 53.
- Uryga A , Gray K , Bennett M. DNA Damage and Repair in Vascular Disease. Annu Rev Physiol. 2016 Feb 10; 78: 45– 66.
- Santulli G. MicroRNAs and Endothelial (Dys) Function. J Cell Physiol. 2016 Aug; 231( 8): 1638– 44.
- Wronska A , Kurkowska-Jastrzebska I , Santulli G. Application of microRNAs in diagnosis and treatment of cardiovascular disease. Acta Physiol (Oxf). 2015 Jan; 213( 1): 60– 83.
- Chen X , Liang H , Zhang J , Zen K , Zhang CY. MicroRNAs are ligands of Toll-like receptors. RNA. 2013 Jun; 19( 6): 737– 9.
- Chamorro-Jorganes A , Araldi E , Suárez Y. MicroRNAs as pharmacological targets in endothelial cell function and dysfunction. Pharmacol Res. 2013 Sep; 75: 15– 27.
- Akhtar S , Hartmann P , Karshovska E , Endothelial Hypoxia-Inducible Factor-1α Promotes Atherosclerosis and Monocyte Recruitment by Upregulating MicroRNA-19a. Hypertension. 2015 Dec; 66( 6): 1220– 6.
- Deshpande D , Kethireddy S , Janero DR , Amiji MM. Therapeutic Efficacy of an omega-3-Fatty Acid-Containing 17-beta Estradiol Nano-Delivery System against Experimental Atherosclerosis. PLoS One. 2016 Feb 3; 11( 2): e0147337.
- Deshpande D , Kethireddy S , Gattacceca F , Amiji M. Comparative pharmacokinetics and tissue distribution analysis of systemically administered 17-β-estradiol and its metabolites in vivo delivered using a cationic nanoemulsion or a peptide-modified nanoemulsion system for targeting atherosclerosis. J Control Release. 2014 Apr 28; 180: 117– 24.
- Rincon MY , VandenDriessche T , Chuah MK. Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation. Cardiovasc Res. 2015 Oct 1; 108( 1): 4– 20.
- Taimeh Z , Loughran J , Birks EJ , Bolli R. Vascular endothelial growth factor in heart failure. Nat Rev Cardiol. 2013 Sep; 10( 9): 519– 30.
- Hassinen I , Hartikainen J , Hedman A , Abstract 11987: Adenoviral intramyocardial VEGF-D gene transfer increases myocardial perfusion in refractory angina patients. Circulation. 2015 Nov 10; 132( Suppl 3): A11987.
- van Wanrooij EJ , de Vos P , Bixel MG , Vestweber D , van Berkel TJ , Kuiper J. Vaccination against CD99 inhibits atherogenesis in low-density lipoprotein receptor-deficient mice. Cardiovasc Res. 2008 Jun 1; 78( 3): 590– 6.
- Nayerossadat N , Maedeh T , Ali PA. Viral and nonviral delivery systems for gene delivery. Adv Biomed Res. 2012; 1: 27.
- Paul A , Hasan A , Kindi HA , Injectable graphene oxide/hydrogel-based angiogenic gene delivery system for vasculogenesis and cardiac repair. ACS Nano. 2014 Aug 26; 8( 8): 8050– 62.
- Poller W , Tank J , Skurk C , Gast M. Cardiovascular RNA interference therapy: the broadening tool and target spectrum. Circ Res. 2013 Aug 16; 113( 5): 588– 602.
- Pradhan-Nabzdyk L , Huang C , LoGerfo FW , Nabzdyk CS. Current siRNA targets in atherosclerosis and aortic aneurysm. Discov Med. 2014 May; 17( 95): 233– 46.
- Wang B , Qian H , Yang H , Xu L , Xu W , Yan J. Regression of atherosclerosis plaques in apolipoprotein E−/− mice after lentivirus-mediated RNA interference of CD40. Int J Cardiol. 2013 Feb 10; 163( 1): 34– 9.
- Koenig O , Walker T , Perle N , New aspects of gene-silencing for the treatment of cardiovascular diseases. Pharmaceuticals (Basel). 2013 Jul 19; 6( 7): 881– 914.
- Kowalski PS , Lintermans LL , Morselt HW , Anti-VCAM-1 and anti-E-selectin SAINT-O-Somes for selective delivery of siRNA into inflammation-activated primary endothelial cells. Mol Pharm. 2013 Aug 5; 10( 8): 3033– 44.
- Hong J , Ku SH , Lee MS , Cardiac RNAi therapy using RAGE siRNA/deoxycholic acid-modified polyethylenimine complexes for myocardial infarction. Biomaterials. 2014 Aug; 35( 26): 7562– 73.
- Nouraee N Mowla SJ. miRNA therapeutics in cardiovascular diseases: promises and problems. Front Genet. 2015 Jun 30; 6: 232.
- Small EM Olson EN. Pervasive roles of microRNAs in cardiovascular biology. Nature. 2011 Jan 20; 469( 7330): 336– 42.
- Suárez Y , Wang C , Manes TD , Pober JS. Cutting edge: TNF-induced microRNAs regulate TNF-induced expression of E-selectin and intercellular adhesion molecule-1 on human endothelial cells: feedback control of inflammation. J Immunol. 2010 Jan 1; 184( 1): 21– 5.
- Soh J , Iqbal J , Queiroz J , Fernandez-Hernando C , Hussain MM. MicroRNA-30c reduces hyperlipidemia and atherosclerosis in mice by decreasing lipid synthesis and lipoprotein secretion. Nat Med. 2013 Jul; 19( 7): 892– 900.
- van Rooij E Kauppinen S. Development of microRNA therapeutics is coming of age. EMBO Mol Med. 2014 Jun 16; 6( 7): 851– 64.
- Lee RG , Crosby J , Baker BF , Graham MJ , Crooke RM. Antisense technology: an emerging platform for cardiovascular disease therapeutics. J Cardiovasc Transl Res. 2013 Dec; 6( 6): 969– 80.
- Rayner KJ , Esau CC , Hussain FN , Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature. 2011 Oct 19; 478( 7369): 404– 7.
- Philippen LE , Dirkx E , Wit JB , Burggraaf K , de Windt LJ , da Costa Martins PA. Antisense MicroRNA Therapeutics in Cardiovascular Disease: Quo Vadis? Mol Ther. 2015 Dec; 23( 12): 1810– 8.
- Kheirolomoom A , Kim CW , Seo JW , Multifunctional Nanoparticles Facilitate Molecular Targeting and miRNA Delivery to Inhibit Atherosclerosis in ApoE(−/−) Mice. ACS Nano. 2015 Sep 22; 9( 9): 8885– 97.
- Wang P , Yang Y , Hong H , Zhang Y , Cai W , Fang D. Aptamers as therapeutics in cardiovascular diseases. Curr Med Chem. 2011; 18( 27): 4169– 74.
DOI: https://doi.org/10.14797/mdcj-12-3-134 | Journal eISSN: 1947-6108
Language: English
Page range: 134 - 140
Published on: Jul 1, 2016
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services
Keywords:
© 2016 Dipti Deshpande, David R. Janero, Victor Segura-Ibarra, Elvin Blanco, Mansoor M. Amiji, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.